Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
J Vasc Surg. 2024 Dec;80(6):1650-1657.e1. doi: 10.1016/j.jvs.2024.08.011. Epub 2024 Aug 13.
Complex endovascular procedures are now recognized as the gold standard treatments for extensive aortic diseases. Bridging stents (covered stents used to couple the aortic graft to the visceral vessels) play a pivotal role, yet there is currently no dedicated device available on the market. The aim of the study was to evaluate the midterm performance of the Gore Viabahn balloon-expandable (VBX) stent graft as a bridging stent for target visceral vessels (TVVs).
Data from all consecutive patients who underwent a fenestrated and branched endovascular aortic repair and received the VBX stent graft as a bridging stent between July 2018 and September 2022 were prospectively collected and subsequently analyzed retrospectively. Primary end points included freedom from TVV instability and freedom from TVV-related reinterventions, both overall and in comparison between branched and fenestrated graft configurations. Secondary end points were overall survival, procedure and TVV-related (in an intent-to-treat basis) technical success, freedom from type IC/IIIC endoleak, and freedom from TVV patency loss.
Sixty-three patients were treated with a fenestrated and branched endovascular aortic repair using the VBX stent graft as a bridging stent, of whom 47 (74.6%) presented an atherosclerotic aneurysm, 7 (11.1%) a post-dissecative aneurysm, and 9 (14.3%) an anastomotic pseudoaneursym or a type IA endoleak in a previous endovascular aortic repair. Included in the aortic repair were 231 of 243 (95.1%) total visceral vessels. The intraoperative requirement of 13 additional VBX stent grafts determined a TVV-related technical success of 94.4%. The mean follow-up was 26.1 ± 16.4 months. The estimated overall survival at 36 months was 73% ± 7.5%. The estimated rates at 36 months for freedom from type IC/IIIC endoleaks and TVV primary patency were 90.6% ± 3.9% and 99% ± 0.7%, respectively. The estimated rate at 36 months for freedom from TVV instability was 92.1% ± 3% and did not differ between branched and fenestrated configurations, whereas freedom from TVV-related reinterventions was 90.6% ± 3.1% and significantly in favor of fenestrations (69.4% vs 96.8%, P < .001). Multivariate analyses confirmed fenestrated configuration as a protective factor against TVV-related reinterventions (hazard ratio: 0.079; 95% confidence interval: 0.016-0.403).
The VBX stent graft proves to be a reliable bridging stent for complex aortic procedures involving both fenestrated and branched endografts. Although immediate results are deemed satisfactory, they favor fenestrations regarding the need of reinterventions through 3 years. The success of the procedure heavily relies on a thorough understanding of the unique characteristics of this stent.
复杂的腔内手术现在被认为是广泛主动脉疾病的金标准治疗方法。覆膜支架(用于将主动脉移植物与内脏血管连接的覆膜支架)起着关键作用,但目前市场上没有专门的设备。本研究旨在评估戈尔 Viabahn 球囊扩张型(VBX)支架作为内脏血管(TVV)桥接支架的中期性能。
前瞻性收集 2018 年 7 月至 2022 年 9 月期间连续接受开窗和分支腔内主动脉修复并使用 VBX 支架作为桥接支架的所有患者的数据,并随后进行回顾性分析。主要终点包括 TVV 不稳定和 TVV 相关再干预的无复发率,包括分支型和开窗型移植物构型之间的比较。次要终点包括总生存率、手术和 TVV 相关(意向治疗基础)技术成功率、无 1C/3C 型内漏和 TVV 通畅率。
63 例患者接受了开窗和分支腔内主动脉修复术,使用 VBX 支架作为桥接支架,其中 47 例(74.6%)为动脉粥样硬化性动脉瘤,7 例(11.1%)为夹层后动脉瘤,9 例(14.3%)为先前腔内主动脉修复的吻合口假性动脉瘤或 1A 型内漏。包括 231 个内脏血管(243 个总内脏血管的 95.1%)。13 个额外的 VBX 支架的术中需求决定了 TVV 相关的技术成功率为 94.4%。平均随访时间为 26.1±16.4 个月。36 个月的总生存率估计为 73%±7.5%。36 个月时 1C/3C 型内漏和 TVV 原发性通畅率的估计率分别为 90.6%±3.9%和 99%±0.7%。36 个月时 TVV 不稳定的估计率为 92.1%±3%,分支型和开窗型构型之间没有差异,而 TVV 相关再干预的无复发率为 90.6%±3.1%,且明显有利于开窗型(69.4%比 96.8%,P<0.001)。多变量分析证实开窗构型是 TVV 相关再干预的保护因素(风险比:0.079;95%置信区间:0.016-0.403)。
VBX 支架被证明是一种可靠的桥接支架,适用于涉及开窗和分支腔内移植物的复杂主动脉手术。尽管即时结果令人满意,但在 3 年内,开窗术式更有利于避免再次干预。手术的成功在很大程度上依赖于对这种支架独特特性的深入理解。